BiotechTube
Home/Pipeline/Lasvic (Lascufloxacin)

Lasvic (Lascufloxacin)

Bacterial Infections

MarketedActive

Key Facts

Indication
Bacterial Infections
Phase
Marketed
Status
Active
Company
KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a publicly listed Japanese pharmaceutical leader with a mission to contribute to people's health by addressing unmet medical needs. Founded in 1923 and publicly listed in 1999, the company has achieved significant scale with a market valuation of ~$94.8B, built on a foundation of established products in respiratory and urology. Its current strategy, outlined in the 'Vision 110' long-term plan, focuses on transforming its business structure to become a core innovator in new pharmaceuticals while expanding its healthcare portfolio.

View full company profile

Therapeutic Areas

RespiratoryUrologyOtolaryngologyInfectious DiseasePain

Other Bacterial Infections Drugs

DrugCompanyPhase
Azithromycin Preparationscspc-pharmaceuticalCommercial
Penem Preparationscspc-pharmaceuticalCommercial
Various Penicillin/Cephalosporin Productscspc-pharmaceuticalCommercial
Nemonoxacin Malate CapsulesZhejiang MedicineCommercial
Generic Portfolio Expansion - Anti-infectivesAlkaloid AD SkopjeRegulatory Submission
Clindamycin Phosphate InjectionViwitCommercial
Levofloxacin Hydrochloride InjectionViwitCommercial
Meropenem-VaborbactamSciClone PharmaceuticalsCommercial (in China)
Vibativ® (telavancin)Cleo Life SciencesApproved
Penicillin V APIBiotikaCommercial
Sterile Injectable Antibiotics PortfolioSteripharmaApproved
Oral AntibioticDawah PharmaceuticalsANDA Filed/Pre-approval